Pharmaceutical company Mayne Pharma (ASX:MYX) is to launch doxycycline in the US.
The pills are a generic alternative to Monodox – an antibacterial for the treatment of a number of infections including severe acne.
The capsules can also be used to treat other skin conditions such as psoriasis.
Mayne Pharma directly markets more than 55 products and has a growing pipeline of around 30 drug products in the US markets.
According to reports – the annual US sales of doxycycline capsules were approximately $US30 million for the 12 months ending 31 January 2018.
Shares in Mayne Pharma (ASX:MYX) are down 1.96 per cent to $0.75